Related Experiment Video
Updated: Jul 30, 2025
Fully Automated Centrifugal Microfluidic Device for Ultrasensitive Protein Detection from Whole Blood
Published on: April 16, 2016
Integrated pipeline for ultrasensitive protein detection in cancer nanomedicine
Chi-An Cheng1, Li-Chiao Chiang1, Yu-Syuan Chu1
1School of Pharmacy, College of Medicine, National Taiwan University Taipei 10050 Taiwan cacheng123@ntu.edu.tw.
Abstract:
Although nanotechnologies have attractive attributes in cancer therapy, their full potential has yet to be realized due to challenges in their translation to clinical settings. The evaluation of cancer nanomedicine efficacy in preclinical in vivo studies is limited to tumor size and animal survival metrics, which do not provide adequate understanding of the nanomedicine's mechanism of action. To address this, we have developed an integrated pipeline called nanoSimoa that combines an ultrasensitive protein detection technique (Simoa) with cancer nanomedicine. As a proof-of concept, we assessed the therapeutic efficacy of an ultrasound-responsive mesoporous silica nanoparticle (MSN) drug delivery system on OVCAR-3 ovarian cancer cells using CCK-8 assays to evaluate cell viability and Simoa assays to measure IL-6 protein levels. The results demonstrated significant reductions in both IL-6 levels and cell viability following nanomedicine treatment. In addition, a Ras Simoa assay (limit of detection: 0.12 pM) was developed to detect and quantify Ras protein levels in OVCAR-3 cells, which are undetectable by commercial enzyme-linked immunosorbent assays (ELISA). These results suggest that nanoSimoa has the potential to guide the development of cancer nanomedicines and predict their behavior in vivo, making it a valuable tool for preclinical testing and accelerating the development of precision medicine if its generalizability is confirmed.
Insights
A new nanoSimoa platform enhances cancer nanomedicine research by measuring protein biomarkers and cell viability. This tool aids in developing more effective cancer therapies and predicting treatment outcomes in preclinical studies.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Cancer nanomedicine faces translation challenges due to limited preclinical efficacy evaluation methods.
- Current methods like tumor size and survival metrics inadequately explain nanomedicine mechanisms of action.
- Bridging the gap between preclinical research and clinical application is crucial for advancing cancer therapy.
Purpose of the Study:
- To develop and validate an integrated pipeline, nanoSimoa, for comprehensive preclinical evaluation of cancer nanomedicines.
- To assess the therapeutic efficacy of an ultrasound-responsive mesoporous silica nanoparticle (MSN) drug delivery system.
- To establish ultrasensitive assays for key protein biomarkers, such as IL-6 and Ras, in cancer cells.
Main Methods:
- Development of the nanoSimoa platform integrating ultrasensitive Simoa assays with cancer nanomedicine.
- Assessment of ovarian cancer cell viability using CCK-8 assays.
- Measurement of IL-6 protein levels and development of a novel Ras Simoa assay (LOD: 0.12 pM) for OVCAR-3 cells.
Main Results:
- Significant reductions in IL-6 protein levels and cell viability were observed after nanomedicine treatment.
- The developed Ras Simoa assay successfully detected and quantified Ras protein, which is undetectable by ELISA.
- nanoSimoa demonstrated potential for detailed mechanistic insights beyond traditional efficacy metrics.
Conclusions:
- The nanoSimoa pipeline offers a powerful tool for evaluating cancer nanomedicine efficacy and mechanism of action.
- This approach can guide the development of novel nanomedicines and predict in vivo behavior.
- nanoSimoa has the potential to accelerate preclinical testing and the advancement of precision cancer medicine.
